换一批Case study 5. Deconvoluting hyperbilirubinemia: differentiating between hepatotoxicity and reversible inhibition of UGT1A1, MRP2, or OATP1B1 in drug development.
第一作者：
Ian,Templeton
第一单位：
Drug Safety Sciences, Janssen Research and Development, Spring House, PA, USA.
作者：
医学主题词
动物(Animals);胆红素(Bilirubin);生物转运(Biological Transport);狗(Dogs);剂量效应关系, 药物(Dose-Response Relationship, Drug);药物发现(Drug Discovery);酶测定(Enzyme Assays);酶抑制剂(Enzyme Inhibitors);葡糖醛酸基转移酶(Glucuronosyltransferase);人类(Humans);高胆红素血症(Hyperbilirubinemia);动力学(Kinetics);肝(Liver);多药耐药相关蛋白质类(Multidrug Resistance-Associated Proteins);有机阴离子转运子(Organic Anion Transporters);大鼠(Rats);危险(Risk)
DOI
10.1007/978-1-62703-758-7_22
PMID
24523126
发布时间
2021-12-03
- 浏览51
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
